OTLK 8-K 2026-09-30
Outlook Therapeutics, Inc. (OTLK) 8-K dated 2026-09-30 — accession 0001104659-26-112356.
Outlook Therapeutics, Inc. (OTLK) is a biotechnology company listed on US.
Outlook Therapeutics, Inc. filed a 8-K on 2026-09-30. Accession 0001104659-26-112356.
This 8-K covers: Listing notice (Item 3.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported OTLK revenue for 2025-06-30 was $1.5M. Net income was -$20.2M. OTLK currently screens at market cap $68.6M.
Not investment advice. The OTLK SEC hub lists recent forms. The stock page is the research view.